Literature DB >> 18773320

The use of exhaled nitric oxide in the management of asthma.

Ian D Pavord1, Dominic Shaw.   

Abstract

It has recently become clear that airways disease associated with eosinophilic airway inflammation, but not other patterns of inflammation, is closely associated with favourable short-and long-term responses to corticosteroid therapy, irrespective of the clinical context in which it occurs. Moreover, a raised exhaled nitric oxide (FE(NO)) is a reasonable marker of eosinophilic airway inflammation, which has a number of advantages as a diagnostic and monitoring tool. In this review we outline essential background information on the use of FE(NO) in clinical practice and discuss some recent work evaluating the clinical value of this technique.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18773320     DOI: 10.1080/02770900801978557

Source DB:  PubMed          Journal:  J Asthma        ISSN: 0277-0903            Impact factor:   2.515


  10 in total

1.  Nasal nitric oxide and lifestyle exposure to tobacco smoke.

Authors:  Haibo Zhou; Baiming Zou; Milan Hazucha; Johnny L Carson
Journal:  Ann Otol Rhinol Laryngol       Date:  2011-07       Impact factor: 1.547

2.  Personalised exhaled nitric oxygen fraction (F ENO)-driven asthma management in primary care: a F ENO subgroup analysis of the ACCURATE trial.

Authors:  Suzanne Boer; Persijn J Honkoop; Rik J B Loijmans; Jiska B Snoeck-Stroband; Willem J J Assendelft; Tjard R J Schermer; Jacob K Sont
Journal:  ERJ Open Res       Date:  2020-09-14

3.  A meta-analysis of the association of exhaled carbon monoxide on asthma and allergic rhinitis.

Authors:  Yu Shaoqing; Zhang Ruxin; Chen Yingjian; Chen Jianqiu; Wang Yanshen; Li Genhong
Journal:  Clin Rev Allergy Immunol       Date:  2011-08       Impact factor: 8.667

4.  Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients.

Authors:  Guiquan Jia; Richard W Erickson; David F Choy; Sofia Mosesova; Lawren C Wu; Owen D Solberg; Aarti Shikotra; Richard Carter; Séverine Audusseau; Qutayba Hamid; Peter Bradding; John V Fahy; Prescott G Woodruff; Jeffrey M Harris; Joseph R Arron
Journal:  J Allergy Clin Immunol       Date:  2012-08-01       Impact factor: 10.793

5.  Exhaled nitric oxide is associated with allergic inflammation in children.

Authors:  Bong Seok Choi; Kyung Won Kim; Yong Ju Lee; Jiyoung Baek; Hyun Bin Park; Yoon Hee Kim; Myung Hyun Sohn; Kyu-Earn Kim
Journal:  J Korean Med Sci       Date:  2011-10-01       Impact factor: 2.153

6.  Asthma control cost-utility randomized trial evaluation (ACCURATE): the goals of asthma treatment.

Authors:  Persijn J Honkoop; Rik J B Loymans; Evelien H Termeer; Jiska B Snoeck-Stroband; Moira J Bakker; Willem J J Assendelft; Peter J Sterk; Gerben Ter Riet; Tjard R J Schermer; Jacob K Sont
Journal:  BMC Pulm Med       Date:  2011-11-24       Impact factor: 3.317

7.  MyAirCoach: the use of home-monitoring and mHealth systems to predict deterioration in asthma control and the occurrence of asthma exacerbations; study protocol of an observational study.

Authors:  Persijn J Honkoop; Andrew Simpson; Matteo Bonini; Jiska B Snoeck-Stroband; Sally Meah; Kian Fan Chung; Omar S Usmani; Stephen Fowler; Jacob K Sont
Journal:  BMJ Open       Date:  2017-01-24       Impact factor: 2.692

8.  Interleukin-13 stimulates production of nitric oxide in cultured human nasal epithelium.

Authors:  Johnny L Carson; Michelle Hernandez; Ilona Jaspers; Katherine Mills; Luisa Brighton; Haibo Zhou; Jing Zhang; Milan J Hazucha
Journal:  In Vitro Cell Dev Biol Anim       Date:  2018-01-29       Impact factor: 2.416

9.  Galectin-10, a potential biomarker of eosinophilic airway inflammation.

Authors:  Justin C Chua; Jo A Douglass; Andrew Gillman; Robyn E O'Hehir; Els N Meeusen
Journal:  PLoS One       Date:  2012-08-06       Impact factor: 3.240

10.  Determinants of Children's Exhaled Nitric Oxide: New Insights from Quantile Regression.

Authors:  Yue Zhang; Kiros Berhane; Sandrah P Eckel; Muhammad T Salam; William S Linn; Edward B Rappaport; Theresa M Bastain; Frank D Gilliland
Journal:  PLoS One       Date:  2015-07-27       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.